Investigating how high levels of the protein MuRF1 contribute to muscle weakness in chronic heart failure patients, to develop new treatment options for these patients and improve their quality of life.
Target validation,
Drug discovery / Therapeutics
One of the major consequences of heart failure is that it causes people to lose muscle mass and strength. This can significantly impact the ability to carry out day to day tasks such as carrying things or walking up the stairs, which can reduce quality of life. There is currently no cure for this loss of muscle strength in heart failure, and little understanding of why and how it occurs.
This project aimed to explore the causes of this muscle weakness, specifically a protein called MuRF1, and test some potential avenues for treatment. The initial approaches used by the team focused on treatments that targeted this protein, however they were not able to confirm an effect on muscle weakness. The team then transitioned to looking at other potential approaches including a dietary intervention and the use of a class of drugs known as SGLT2 inhibitors that are already widely available. In both laboratory and human models, it was found that this treatment could have a positive effect on the muscle weakness that develops with heart failure.
Additionally, this work revealed more information about the causes of muscle weakness, which provides avenues for new treatment studies in the future. Overall, this project has made significant contributions to our understanding of muscle weakness in heart failure and how we may be able to treat it.
Funding has been acquired to continue the investigations into this area of study and a number of publications have been made in major journals.
The development of a new AI-supported model for imaging the heart based on data from over 700 people with atrial fibrillation, allow ablation to be more personalised to individual patients.
Developing a new, low-cost blood test to diagnose heart failure earlier, outside of hospital, and in the community, enabling patients to receive more personalised care, reducing costs and hospital admissions.
Bringing together patients and medical professionals to establish a partnership aimed at identifying areas of priority in adult cardiac surgery, to better inform clinicians and make heart surgery safer for patients.
Developing an AI-assisted computer programme to identify whether a conduction system pacing (CSP) procedure has been successful, which will allow more patients to benefit from this innovative pacemaker technology.
Your gifts fund our life saving project